June 29, 2020 / 11:39 AM / 14 days ago

BRIEF-An Open Letter From Daniel O’Day, Chairman & CEO, Gilead Sciences

June 29 (Reuters) - Gilead Sciences Inc:

* AN OPEN LETTER FROM DANIEL O’DAY, CHAIRMAN & CEO, GILEAD SCIENCES

* GILEAD SCIENCES INC - HAVE SET REMDESIVIR PRICE FOR GOVERNMENTS OF DEVELOPED COUNTRIES OF $390 PER VIAL

* GILEAD SCIENCES INC - IN U.S., SAME GOVERNMENT PRICE OF $390 PER VIAL FOR REMDESIVIR WILL APPLY

* GILEAD SCIENCES INC - PRICE FOR U.S. PRIVATE INSURANCE COMPANIES, WILL BE $520 PER VIAL FOR REMDESIVIR

* GILEAD SCIENCES INC - ENTERED INTO AGREEMENT WITH HHS WHEREBY HHS AND STATES WILL CONTINUE TO MANAGE ALLOCATION TO HOSPITALS UNTIL END OF SEPT.

* GILEAD SCIENCES - MAJORITY OF PATIENTS ARE EXPECTED TO RECEIVE 5-DAY TREATMENT COURSE USING 6 VIALS OF REMDESIVIR, EQUATES TO $2,340/ PATIENT

* GILEAD SCIENCES INC - ONCE SUPPLIES OF REMDESIVIR ARE LESS CONSTRAINED, HHS WILL NO LONGER MANAGE ALLOCATION

* GILEAD SCIENCES INC - HAVE SET REMDESIVIR PRICE FOR GOVERNMENTS OF DEVELOPED COUNTRIES OF $390 PER VIAL

* GILEAD SCIENCES SAYS “AS WITH MANY OTHER ASPECTS OF THIS PANDEMIC, WE ARE IN UNCHARTERED TERRITORY IN PRICING REMDESIVIR”

* GILEAD SCIENCES - EXPECT INVESTMENT ON DEVELOPMENT AND MANUFACTURE OF REMDESIVIR TO EXCEED $1 BILLION (U.S.)

* GILEAD SCIENCES SAYS DISCOUNTED PRICE ON REMDESIVIR TO A LEVEL THAT IS AFFORDABLE FOR DEVELOPED COUNTRIES WITH LOWEST PURCHASING POWER Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below